Prostate Cancer Diagnostics Market Is Anticipated to Expand at a CAGR of 14.1% During the Forecast Period 2021-2028
Prostate cancer is a type of cancer that is developed in the prostate gland and it can spread by breaking away from prostate tumors. The prostate gland is found only in men and is located below the bladder. Adenocarcinomas, small cell carcinomas, neuroendocrine tumors (other than small cell carcinomas), transitional cell carcinomas, and sarcomas are a type of prostate cancer. Prostate cancer can be diagnosed by ultrasound, collecting a sample of prostate tissue, MRI fusion, and biopsy.
Rising cases of prostate cancer around the globe are a prime factor fueling the market growth. According to the report published in April 2018, by “Our World in Data” in 2017, 9.6 million people are estimated to have died from various forms of cancer. Every sixth death in the world is due to cancer, making it the second leading cause of death. Moreover, increasing the launch of innovative prostate cancer diagnostic devices is another major factor serving as a growth factor. For instance, in July 2019, Diagnostics developer MDNA Life Sciences has partnered with Aspire Pharma to introduce the new Mitomic Prostate Test (MPT) for clinical use in the UK. The blood test is intended to identify individuals with clinically significant prostate cancer or those who require treatment. It analyses mitochondrial DNA as biomarkers to determine whether a man has or does not have cancer.
Request for Sample Copy of Report with Analysis of COVID-19 Impact on Prostate Cancer Diagnostics Market – https://www.stratagemmarketinsights.com/sample/12208
From the geographical perspective, North America is expected to gain significant growth over the forecast period and this can be attributed to the high prevalence of prostate cancer in the region. According to the U.S. Department of Health and Human Services, in 2019, the number of new cases of prostate cancer was 174,650, and death cases were approx. 31,620.
However, the high cost of the diagnosis and treatment of prostate cancer is expected to hamper the market growth.
Competitive Landscape –
Genomic Health, Abbott, OPKO, Siemens Healthcare, DiaSorin, BioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics
Market Segmentation –
By Product Type, the market is primarily segmented into:
- Tumor Biomarker Tests
By Applications, the market is segmented into:
- Age < 55
- Age 55-75
- Age > 75
Key Developments –
- In September 2019, the Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic castration-sensitive prostate cancer (mCSPC).
- In October 2019, GE Healthcare has formed a global alliance with Theragnostics for the commercialization of a prostate-specific membrane antigen (PSMA) PET / CT imaging agent, GalliProst. The diagnostic is designed to help visualize prostate cancer, offering information on the status of the disease and allowing personalized treatment.
- In September 2019, Koelis SAS (“Koelis” or the “Company”) and InnovaHealth Partners, LP (“InnovaHealth”) jointly announced today along with Medevice Partners (“Medevice”). Koelis is a leading innovator in the market for image-guided systems for prostate cancer diagnosis and treatment.
Reasons to Purchase this Report:
- The trendy developments, market shares, and strategies that are employed by means of the essential market players
- The segment that is anticipated to dominate the market as properly as the segment which holds the highest CAGR in the forecast period
- Current and future of global Prostate Cancer Diagnostics market outlook in the developed and rising markets
- Regions/countries that are anticipated to witness the quickest growth rates at some stage in the forecast period
Buy Now This Premium Report to Grow your Business: https://www.stratagemmarketinsights.com/cart/12208
Table of Contents –
Section 1 Prostate Cancer Diagnostics Product Definition
Section 2 Global Prostate Cancer Diagnostics Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Prostate Cancer Diagnostics Shipments
2.2 Global Manufacturer Prostate Cancer Diagnostics Business Revenue
2.3 Global Prostate Cancer Diagnostics Market Overview
Section 3 Manufacturer Prostate Cancer Diagnostics Business Introduction
3.1 Genomic Health Prostate Cancer Diagnostics Business Introduction
3.1.1 Genomic Health Prostate Cancer Diagnostics Shipments, Price, Revenue and Gross profit 2015-2020
3.1.2 Genomic Health Prostate Cancer Diagnostics Business Distribution by Region
3.1.3 Genomic Health Interview Record
3.1.4 Genomic Health Prostate Cancer Diagnostics Business Profile
3.1.5 Genomic Health Prostate Cancer Diagnostics Product Specification
3.2 Abbott Prostate Cancer Diagnostics Business Introduction
3.2.1 Abbott Prostate Cancer Diagnostics Shipments, Price, Revenue and Gross profit 2015-2020
3.2.2 Abbott Prostate Cancer Diagnostics Business Distribution by Region
3.2.3 Interview Record
3.2.4 Abbott Prostate Cancer Diagnostics Business Overview
3.2.5 Abbott Prostate Cancer Diagnostics Product Specification
Section 11 Prostate Cancer Diagnostics Cost of Production Analysis
11.1 Raw Material Cost Analysis
11.2 Technology Cost Analysis
11.3 Labor Cost Analysis
11.4 Cost Overview
Section 12 Conclusion
Inquire To Know More About This Report @ https://www.stratagemmarketinsights.com/quiry/12208
Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with a cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide.
We strive to offer sapient solutions, expert consultations, and tailored/customized solutions. Our team includes analysts that leverage their years of experience and expertise to create accurate and error-free reports. The domain-specific teams are constantly focused on tracking markets, aiding our clients to gain a competitive edge through high-quality market intelligence. We offer an array of services including, syndicated research, advisory and consulting research process outsourcing, and content management.
Stratagem Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027 / JAPAN +815055391737
- CDN Newswire